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based on para-aminosalicylic acid—zinc layered hydroxide nanocomposites 
 
Abstract 
Tuberculosis is a lethal epidemic, difficult to control disease, claiming thousands of lives 
every year. We have developed a nanodelivery formulation based on para-aminosalicylic acid 
(PAS) and zinc layered hydroxide using zinc nitrate salt as a precursor. The developed 
formulation has a fourfold higher efficacy of PAS against mycobacterium tuberculosis with a 
minimum inhibitory concentration (MIC) found to be at 1.40 μg/mL compared to the free 
drug PAS with a MIC of 5.0 μg/mL. The newly developed formulation was also found active 
against Gram-positive bacteria, Gram-negative bacteria, and Candida albicans. The 
formulation was also found to be biocompatible with human normal lung cells MRC-5 and 
mouse fibroblast cells-3T3. The in vitro release of PAS from the formulation was found to be 
sustained in a human body simulated phosphate buffer saline (PBS) solution at pH values of 
7.4 and 4.8. Most importantly the nanocomposite prepared using zinc nitrate salt was 
advantageous in terms of yield and free from toxic zinc oxide contamination and had higher 
biocompatibility compared to one prepared using a zinc oxide precursor. In summary, these 
promising in vitro results are highly encouraging for the continued investigation of para-
aminosalicylic acid and zinc layered hydroxide nanocomposites in vivo and eventual 
preclinical studies. 
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